Power Michael S. Rosol - 27 Dec 2021 Form 4/A - Amendment Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.

Role
Chief Medical Officer
Signature
/s/ Erika L. Eves for Michael S. Rosol, by power of attorney
Issuer symbol
N/A
Transactions as of
27 Dec 2021
Net transactions value
+$100
Form type
4/A - Amendment
Filing time
08 Mar 2022, 15:01:38 UTC
Date Of Original Report
29 Dec 2021
Next filing
18 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAVB Stock Option Award $100 +100,000 $0.001000* 100,000 27 Dec 2021 Common Stock 100,000 $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest quarterly over a four-year period beginning on April 1, 2022.